Jaguar Health reported a decline in Q1 2025 revenue compared to both the prior quarter and the prior year, primarily driven by a significant drop in prescription product revenue. The company also saw an increase in its operating loss and net loss, alongside higher sales and marketing expenses.
Mytesi prescription volume increased by approximately 1.8% in Q1 2025 over Q1 2024.
positiveLicense fees of $42,500 recognized from a securities purchase agreement with a European partner.
neutralR&D expense decreased by $0.6 million, primarily due to the conclusion of the Phase 3 OnTarget clinical trial.
neutralCombined net revenue for prescription products decreased by approximately 37% versus net Q4 2024 revenue of $3.5 million and approximately 6% versus net Q1 2024 revenue of $2.4 million.
negativeMytesi prescription volume decreased by approximately 13.5% in Q1 2025 over Q4 2024.
negativeLoss from operations increased by $1.2 million, from $8.2 million in Q1 2024 to $9.4 million in Q1 2025.
negativeNet loss attributable to common stockholders increased by approximately $1.2 million, from $9.2 million in Q1 2024 to $10.4 million in Q1 2025.
negativeSales and Marketing expense increased by approximately $1.1 million, from $1.4 million in Q1 2024 to $2.5 million in Q1 2025.
attentionGeneral and Administrative expense increased by approximately $0.5 million, from $4.4 million in Q1 2024 to $4.9 million in Q1 2025, largely due to increased legal expenses.
attentionMargin metrics will be available once backend extracts data from insights_json
| Segment | Current | Prior Yr | YoY | % Total |
|---|---|---|---|---|
Prescription Products | N/A | — | — | — |
License Revenue | N/A | — | — | — |
Non-prescription Neonorm products | N/A | — | — | — |
| Total Revenue | $0.00M | — | — | 100.0% |
Segment performance shows business unit health and growth drivers.
Focus on advancing crofelemer pipeline for rare diseases (MVID, SBS-IF, breast cancer).
Acknowledging revenue decrease in prescription products compared to prior periods.
Highlighting increased sales and marketing expenses for market access and Gelclair launch.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.